CoChat

Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist

Open access

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index; 7 of the 34 sources its claims cite were checked for support.

Abstract

We assessed the effect of the prandial state on the pharmacokinetics, safety, and tolerability of single and multiple doses of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide 1 receptor agonist (GLP-1 RA), in two studies (A and B). Study A and study B were phase 1, randomized, crossover studies in healthy adults aged 18–65 years and 21–70 years, respectively. Participants received single (3 mg, study A) or multiple (16 mg, study B) oral doses of orforglipron under fasted and fed conditions. Blood samples were collected pre- and postdose to assess area under the concentration–time curve (AUC), maximum observed drug concentration ( C max ), time of C max ( t max ), and half-life ( t 1/2 ) associated with terminal rate constant. AUC and C max were analyzed using a linear mixed-effects model. Treatment differences were presented as ratios of geometric least squares means (GLSM). Treatment-emergent adverse events (TEAEs), adverse events of special interest, and serious adverse events were assessed. Study A included 12 participants (mean age 45.0 years; male 66.7%); study B included 34 participants (mean age 42.8 years; male 88.2%). GLSM AUC and C max were lower by 23.7% and 23.2% in study A, and 17.6% and 20.9% in study B, in the fed versus fasted states, respectively. In both studies, t 1/2 and median t max were comparable between fed and fasted states. The majority of TEAEs in both studies were gastrointestinal tract-related conditions. No serious adverse events or deaths were reported in either study. The observed pharmacokinetic differences due to the prandial state are unlikely to contribute to clinically meaningful differences in the efficacy of orforglipron. The safety profile was consistent with the known profiles of other GLP-1 RAs. Given the absence of prandial restrictions, orforglipron may emerge as a convenient oral treatment option for patients with type 2 diabetes or obesity. ClinicalTrials.gov identifiers, NCT03929744 and NCT05110794.

Overview

CoChat Summary

TL;DR

In two phase 1 crossover studies in healthy adults, oral orforglipron exposure was modestly lower when given with food than fasted, with AUC and Cmax reductions of up to about 24%. The authors conclude these pharmacokinetic differences are unlikely to be clinically meaningful, and the safety profile was consistent with other GLP-1 receptor agonists.

Key findings

  • Fed versus fasted geometric least squares mean AUC and Cmax were lower: in Study A (single 3 mg), AUC0–∞ was 23.7% lower and Cmax 23.2% lower; in Study B (multiple 16 mg), AUC0–24 was 17.6% lower and Cmax 20.9% lower.
  • t1/2 and median tmax were comparable between fed and fasted states: Study A geometric mean t1/2 was 29.5 h fasted vs 27.9 h fed; Study B was 26.0 h fasted vs 24.6 h fed; median tmax was 8.0 h in both states in both studies, with no statistical difference (Study A p = 0.6875; Study B p = 0.0529).
  • Most treatment-emergent adverse events were gastrointestinal; no serious adverse events or deaths occurred. Study A had TEAEs in 2/12 (16.7%) fasted and 0/12 fed; Study B had TEAEs in 18/28 (64.3%) fasted and 12/27 (44.4%) fed, with one participant (3.6%) discontinuing due to vomiting in the fasted condition.
  • The authors state the observed PK differences due to prandial state are unlikely to contribute to clinically meaningful differences in efficacy, and orforglipron may offer convenience given the absence of prandial restrictions.

Methods

  • Two phase 1, randomized, crossover studies in healthy adults: Study A (NCT03929744) tested a single 3 mg oral dose under fasted and fed conditions with a ~500 kcal meal (50% carbohydrate, 30% fat, 20% protein) and ≥5-day washout; Study B (NCT05110794) tested multiple 16 mg doses after titration under fasted and fed conditions with a ~800–1000 kcal high-fat meal (50% fat, 25–30% carbohydrate, 15–19% protein).
  • PK parameters included AUC, Cmax, tmax, and t1/2; AUC and Cmax were log-transformed and analyzed with a linear mixed-effects model using treatment, period, and sequence as fixed effects and participant within sequence as random, with fed/fasted GLSM ratios and 90% CIs; tmax was analyzed non-parametrically using the Wilcoxon signed-rank test.
  • Participants were overtly healthy men and women not of child-bearing potential: Study A included 12 participants aged 18–65 years with BMI 20–40 kg/m² and HbA1c <6.5%; Study B included 34 participants aged 21–70 years with BMI 18.5–35.0 kg/m² and specified hemoglobin thresholds.

Limitations

  • The paper states both phase 1 studies included overtly healthy people, most of whom were male, and had small sample sizes; the results enabled phase 2 studies outside the clinical setting where dosing-condition compliance cannot be fully ensured, and ongoing phase 3 ACHIEVE and ATTAIN studies will further assess safety and efficacy regardless of prandial state.
  • Evident from the text: Study B enrolled 34 participants but PK analyses included 28 fasted and 27 fed participants, with exclusions due to emesis affecting PK calculations, one discontinuation before treatment due to urticaria, and t1/2 not calculable for some participants because of insufficient quantifiable concentrations or poor adjusted R².
  • Evident from the text: both studies were conducted at single centers, in healthy participants rather than patients with type 2 diabetes or obesity, and the food-effect assessments used specific standardized meals, so generalizability to other meals or patient populations is not established here.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s13300-024-01554-1

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 a Study A design. There was a washout period of ≥ 5 days between each dose. In each treatment period, participants remained in the clinical research unit at least until completion of assessments on day 4 and returned for an outpatient visit on day 5. Participants were randomly assigned to one of two treatment sequences. Treatment sequence 1—Period 1: Fasted treatment; Period 2: Food-effect treatment or fed treatment. Treatment sequence 2—Period 1: Food-effect treatment or fed treatment; Period 2: Fasted treatment. OFG orforglipron. b Study B design. PK pharmacokinetic
Fig. 1 a Study A design. There was a washout period of ≥ 5 days between each dose. In each treatment period, participants remained in the clinical research unit at least until completion of assessments on day 4 and returned for an outpatient visit on day 5. Participants were randomly assigned to one of two treatment sequences. Treatment sequence 1—Period 1: Fasted treatment; Period 2: Food-effect treatment or fed treatment. Treatment sequence 2—Period 1: Food-effect treatment or fed treatment; Period 2: Fasted treatment. OFG orforglipron. b Study B design. PK pharmacokineticCC BY-NC · PubMed Central
Fig. 2 a Plasma concentration profile of orforglipron (3 mg) after single oral administration to healthy subjects in the fasted and fed states in study A. b Plasma concentration profile of orforglipron (16 mg) after multiple oral administration to healthy participants in the fasted and fed states in study B. Data in graph are arithmetic mean (+ 1 SD). OFG orforglipron
Fig. 2 a Plasma concentration profile of orforglipron (3 mg) after single oral administration to healthy subjects in the fasted and fed states in study A. b Plasma concentration profile of orforglipron (16 mg) after multiple oral administration to healthy participants in the fasted and fed states in study B. Data in graph are arithmetic mean (+ 1 SD). OFG orforglipronCC BY-NC · PubMed Central

Verification

Claims the paper makes

5 Valid · 0 Not valid · 19 Not checked · 44 Own results and interpretations

23 more claims

Create a free account to see all 68 claims and to verify the 27 references still open.

See all claims — free account
  • Probably not a substantial claim. 25
  • It may state two separate claims as one. 21
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2022;46(Suppl_1):S140–57.

Cited by

See all 39

Metadata

Authors
Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W.
Affiliations
Eli Lilly (United States) (US)
Corresponding author
Ma, Xiaosu
Venue
Diabetes Therapy
Published
2024-02-24
Volume
15
Issue
4
Pages
819-832
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4392138369
Cited by
38
References
34
Citations by year
2026: 20 · 2025: 17 · 2024: 1
FWCI
12.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
orforglipron, GLP-1 receptor agonists, food effect, prandial state, pharmacokinetics, drug safety and tolerability, gastrointestinal adverse effects, type 2 diabetes, obesity, oral administration, linear mixed models, area under the curve, half-life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. https://app.cochat.ai/papers/10.1007/s13300-024-01554-1
The paper
Ma, X., Liu, R., Pratt, E. J., Benson, C. T., Bhattachar, S. N., & Sloop, K. W. (2024). Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Therapy. https://doi.org/10.1007/s13300-024-01554-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.